(Q28209431)

1

0 references

Hanne Havsteen

2

0 references

Kamma Bertelsen

4

0 references

Anders Jakobsen

What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods

5

0 references

language of work or name

English

0 references

publication date

February 2003

0 references

published in

Gynecologic Oncology

0 references

volume

88

0 references

issue

2

0 references

page(s)

118-22

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Hexamethylmelamine: pharmacology and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Hexamethylmelamine as a single second-line agent in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of gemcitabine in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021

Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900103-8

7 January 2021